title: Durable clinical activity of single-agent bevacizumab in a nonagenarian patient with metastatic alveolar soft part sarcoma.
abstract: Alveolar soft part sarcoma is a rare malignancy usually considered resistant to conventional chemotherapy, but recent data suggest that the multikinase inhibitors sunitinib and cediranib could be active in this setting. A 90-year-old lady with alveolar soft part sarcoma of the leg and lung metastases was started on sunitinib 37.5 mg daily. The treatment was poorly tolerated with grade 3 hypertension and grade 3 thrombocytopenia, which persisted after dose reduction to 25 mg daily. The patient was subsequently started on bevacizumab 10 mg/kg every 2 weeks, resulting in a marked improvement in pain and a partial response on lung metastases for 16 months and ongoing. Agents targeting the vascular endothelial growth factor-signalling pathway seem to exert clinically relevant and prolonged activity against alveolar soft part sarcoma and deserve further evaluation in the treatment of this rare soft tissue sarcoma.
authors.affiliation: Sarcoma Unit, Cochin Teaching Hospital, Université Paris Descartes, France. olivier.mir@cch.aphp.fr
authors.forename: Olivier
authors.initials: O
authors.lastname: Mir
authors.forename: Pascaline
authors.initials: P
authors.lastname: Boudou-Rouquette
authors.forename: Frédérique
authors.initials: F
authors.lastname: Larousserie
authors.forename: Benoit
authors.initials: B
authors.lastname: Blanchet
authors.forename: Antoine
authors.initials: A
authors.lastname: Babinet
authors.forename: Philippe
authors.initials: P
authors.lastname: Anract
authors.forename: François
authors.initials: F
authors.lastname: Goldwasser
mesh_terms: D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068258:Bevacizumab; D005260:Female; D006801:Humans; D007866:Leg / Q000473:pathology; D008168:Lung / Q000000981:diagnostic imaging; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary*; D011859:Radiography; D018234:Sarcoma, Alveolar Soft Part / Q000188:drug therapy*; D012983:Soft Tissue Neoplasms / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab